NE UpdatesHappeningsBreaking News

Assam govt issues revised protocol for hospitalisation, treatment & discharge from Hospitals of Covid patients

Jan. 11: The Assam Government on Tuesday issued revised Protocol for Hospitalisation, Treatment and Discharge from Hospitals in respect of Covid-19 Patients. In supersession of all the earlier notifications issued for treatment protocol for COVID•19 patients in Assam, the Health & Family Welfare Department notified the ‘Revised Protocol.

Further, patients who are not vaccinated or who have not taken the second dose of vaccine despite being due or overdue shall not be provided free treatment facilities including for expenses in the Government Hospitals/ CCC. Those patents occupying paying cabins irrespective of vaccination status shall pay for the services. The diet of the COVID patients in the government hospitals shall be at par with the hospital diet. However, in the Hospitals/ COVID Care Centres, up to Rs 200 shall be allowed per patient per day considering the packaging costs.

The district administration shall strictly restrict expenditure as per the patient admission on per head basis. BPL patients shall be given free diet and others may purchase their food or get delivered from home. The Principals of all medical colleges are empowered to cancel the vacation of the faculty or recall them for service as per need.

All Asymptomatic Covid -19 Positive patients shall preferably be isolated at home if facility for isolation exists, or in a designated facility (CCC) for a total period of 7 (SEVEN) days instead of 10 days.

MANAGEMENT OF COVID-19 (January, 2022):

A. ASYMPTOMATIC PATIENTS:  All asymptomatic Cove-19 positive patients should preferably be isolated at home .if facility for isolation exists or in a designated facility (CCC), for a total period of 10 days, by observing the following:

  1. Place the patient in a well -ventilated single room
  2. Limit the movement of the patient in the house and minimize shared space. Ensure that shared spaces (eg. kitchen, bathroom) are well ventilated.
  3. Visitors should not be allowed until the patient is discharged.
  4. Perform hand hygiene after any type of contact with patents or their immediate environment
  5. To contain respiratory secretions, a medical mask should be provided to the patient and worn as much as possible and changed daily
  6. Use dedicated linen and eating utensils for the patient
  7. Strict regular surface cleaning to be maintained
  8. If the patient develops symptoms he/she is to be transferred to a dedicated COVID hospital.
  9. Released from institutional isolation (CCC) as per discharge protocol
  10. After discharge from institutional isolation, they are advised home quarantine with the following instructions:  Wear a triple-layered surgical mask,  Live in a single room with good ventilation, Avoid close contact with family members, Eat separately ,Keep hands clean and avoid outdoor activities, Self monitoring of the symptoms.

B. CRITERIA FOR HOSPITALIZATION OF COVID-19 POSITIVE CASES IN DESIGNATED COVID HOSPITALS:

  1. All elderly Covid Positive patients above the age of 70 years irrespective of their co-morbidities and symptoms
  2. All Covid positive patients above the ago of 60 years having major co-morbidities like uncontrolled diabetes * Hypertension, kidney diseases. lung diseases, cancer, organ transplant recipient etc
  3. All Covid-19 positive patents with respiratory distress (SPO2 <94% in room air, respiratory rate >24/minute).

C MANAGEMENT OF MILD CASES:

  1. Mild cases are those with low grade fever/ cough/ malaise/rhinorrhea/ sore throat without any shortness of breath
  2. Admission in COVID care centers (CCC).
  3. Contact and droplet precautions, strict hand hygiene
  4. Symptomatic treatment: Paracetamol, cough syrup, Gargle with warm saline, Tab. Zinc 50 mg/day, Tab Vitamin-C 500 mg twice daily, Tab Vitamin D3 60 K once weekly, e Tab Famotidin 20 mg BD.
  5. Antibiotics: Azithromycin 500 mg daily for 5 days or Amoxyclav (500+125) mg 8 hourly for 5 days
  6. Cocktail antibodies( Casirivimab and Imdevimab) can be consider in patents with (a) Male or female > 18 years of age having high risk factors for progression of disease (b) Has (SARS-COV-2) infection as diagnosed by validated Sars-CoV-2 antigen, RT-PCR or other molecular diagnostic assay.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected !!
Close
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker